SYNERGY BETWEEN LOW MOLECULAR WEIGHT HEPARIN AND PLATELET AGGREGATION INHIBITORS, PROVIDING A COMBINATION THERAPY FOR THE PREVENTION AND TREATMENT OF VARIOUS THROMBOEMBOLIC DISORDERS

摘要

This invention is directed to a combination therapy comprising the administration of a low molecular weight heparin such as tinzaparin and a platelet GPIIb/IIIa antagonist such as roxifiban for treating, preventing and reducing the risk of thromboembolic disorders.